

# Valter Torri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2175237/publications.pdf>

Version: 2024-02-01

323  
papers

32,355  
citations

6254

80  
h-index

4432

172  
g-index

333  
all docs

333  
docs citations

333  
times ranked

32026  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	1.1	9
2	Tumor-associated macrophages and risk of recurrence in stage III colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 307-312.	3.0	5
3	Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100335.	1.1	7
4	Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. <i>Clinical Lung Cancer</i> , 2021, 22, 361-370.e3.	2.6	8
5	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
6	Heme catabolism by tumor-associated macrophages controls metastasis formation. <i>Nature Immunology</i> , 2021, 22, 595-606.	14.5	59
7	Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in Northern Italy: A nomogram to predict unfavorable outcome. <i>European Journal of Radiology</i> , 2021, 137, 109612.	2.6	18
8	Pozitotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. <i>European Journal of Cancer</i> , 2021, 149, 235-248.	2.8	46
9	SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy. <i>Scientific Reports</i> , 2021, 11, 12312.	3.3	17
10	Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 121-126.	3.5	23
11	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	1.4	0
12	To Continue or Not to Continue? That Is the Question. <i>Journal of Clinical Oncology</i> , 2020, 38, 3830-3832.	1.6	2
13	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	4.5	94
14	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	16.8	6
15	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020, 9, 617-628.	2.8	8
16	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA). <i>Lancet Oncology</i> , 2020, 21, 1620-1629.	10.7	152
17	Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088). <i>Trials</i> , 2020, 21, 678.	1.6	2
18	Immunometabolic Status of COVID-19 Cancer Patients. <i>Physiological Reviews</i> , 2020, 100, 1839-1850.	28.8	20

#	ARTICLE	IF	CITATIONS
19	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. <i>ESMO Open</i> , 2020, 5, e000748.	4.5	2
20	Factors Affecting Mortality in 1022 COVID-19 Patients Referred to an Emergency Department in Bergamo during the Peak of the Pandemic. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1313-1318.	0.6	3
21	Implementing clinical practice guidelines: time to assess it. <i>ESMO Open</i> , 2020, 5, e001130.	4.5	0
22	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	16.8	51
23	Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial. <i>Trials</i> , 2020, 21, 401.	1.6	37
24	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	10.7	503
25	Evaluation of a Primary Open-Angle Glaucoma Prediction Model Using Long-term Intraocular Pressure Variability Data. <i>JAMA Ophthalmology</i> , 2020, 138, 780.	2.5	12
26	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-“Small-Cell Lung Cancer: An External Validation. <i>Clinical Lung Cancer</i> , 2020, 21, e337-e348.	2.6	6
27	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	2.3	56
28	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , 2020, 105, 2592-2597.	3.5	29
29	Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2020, 139, 104815.	4.4	19
30	Turn off pain: What has changed 4 years later?. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 2428-2429.	1.5	0
31	Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDx study. <i>Breast</i> , 2020, 52, 1-7.	2.2	8
32	Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA1111-LBA1111.	1.6	34
33	Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. , 2020, , .		0
34	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. <i>PLoS ONE</i> , 2019, 14, e0220644.	2.5	6
35	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	2.8	11
36	Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. <i>Breast</i> , 2019, 48, 7-16.	2.2	37

#	ARTICLE	IF	CITATIONS
37	Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2019, 121, 744-750.	6.4	10
38	RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1232-1233.	6.3	0
39	Gadoxetate Disodium-enhanced MR Cholangiography for Evaluation of Biliary-Enteric Anastomoses: Added Value Beyond Conventional T2-Weighted Images. <i>American Journal of Roentgenology</i> , 2019, 213, W123-W133.	2.2	4
40	Assessing assumptions for statistical analyses in randomised clinical trials. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 185-189.	3.5	23
41	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	4.5	151
42	Prognostic nutritional index as a prognostic marker in glioblastoma: Data from a cohort of 282 Italian patients. <i>Journal of the Neurological Sciences</i> , 2019, 400, 175-179.	0.6	16
43	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019, 75, 39-51.	7.7	124
44	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	2.0	12
45	The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. <i>European Journal of Cancer</i> , 2019, 111, 1-7.	2.8	12
46	Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 455-462.	2.9	17
47	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. <i>Cancer Immunology Research</i> , 2019, 7, 751-758.	3.4	29
48	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	3.7	95
49	Standard (8-weeks) vs long (12-weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). <i>BMC Cancer</i> , 2019, 19, 1215.	2.6	10
50	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	3.7	57
51	Turn off pain evaluates the quality of pain care provided for paediatric inpatients. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2019, 108, 16-18.	1.5	1
52	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	7.0	315
53	Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. <i>Advances in Therapy</i> , 2019, 36, 381-406.	2.9	19
54	Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 301-318.	2.3	1

#	ARTICLE	IF	CITATIONS
55	Exploiting Fasting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019, 20, e413-e417.	2.6	27
56	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	1.4	5
57	Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3501-3501.	1.6	30
58	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
59	Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients. <i>Journal of the Neurological Sciences</i> , 2018, 390, 14-19.	0.6	7
60	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2â€“3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 413-423.	8.1	180
61	Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images. <i>Radiology</i> , 2018, 287, 933-943.	7.3	70
62	Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study. <i>Scientific Reports</i> , 2018, 8, 619.	3.3	36
63	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188.	27.0	699
64	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	10.7	486
65	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2018, 3, e000389.	4.5	4
66	The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results. <i>Journal of Glaucoma</i> , 2018, 27, 856-863.	1.6	14
67	Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. <i>British Journal of Cancer</i> , 2018, 119, 1456-1463.	6.4	43
68	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	7.7	38
69	Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis. <i>ESMO Open</i> , 2018, 3, e000327.	4.5	2
70	Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. <i>Cancer Research</i> , 2018, 78, 5729-5730.	0.9	11
71	Soluble stromaâ€“related biomarkers of pancreaticÂcancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	56
72	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	6.4	15

#	ARTICLE	IF	CITATIONS
73	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e811-e814.	2.6	15
74	International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3594-3594.	1.6	5
75	Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3599-3599.	1.6	6
76	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-581.	1.6	3
77	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. <i>Oncotarget</i> , 2018, 9, 31877-31887.	1.8	4
78	Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13076-e13076.	1.6	0
79	A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21101-e21101.	1.6	0
80	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017, 28, 1230-1242.	1.2	168
81	Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis. <i>Blood Purification</i> , 2017, 44, 77-88.	1.8	22
82	Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials. <i>Clinical Breast Cancer</i> , 2017, 17, 433-440.	2.4	6
83	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 752-762.	1.1	17
84	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017, 20, 825-833.	5.3	32
85	The Glaucoma Italian Pediatric Study (GIPSy): 1-Year Results. <i>Journal of Glaucoma</i> , 2017, 26, 987-994.	1.6	7
86	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	4.6	258
87	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	1.4	149
88	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	2.8	25
89	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. <i>Lancet Oncology</i> , 2017, 18, 1221-1237.	10.7	226
90	Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2 <sup>-</sup> ) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. <i>Breast</i> , 2017, 35, 115-121.	2.2	21

#	ARTICLE	IF	CITATIONS
91	Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1536-1541.	1.0	13
92	Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients's™ Need. Preliminary Results of the Victor-6 Study. <i>Breast</i> , 2017, 36, S48-S49.	2.2	0
93	Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 313-322.	0.8	134
94	Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e61-e72.	2.3	18
95	Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study. <i>Tumori</i> , 2017, 103, e4-e8.	1.1	17
96	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	1.6	143
97	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA1-LBA1.	1.6	17
98	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA1-LBA1.	1.6	31
99	The prognostic role of tumor size in early breast cancer in the era of molecular biology. <i>PLoS ONE</i> , 2017, 12, e0189127.	2.5	24
100	<scp>ACROSCORE</scp>: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease. <i>Clinical Endocrinology</i> , 2016, 84, 380-385.	2.4	24
101	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq1 1 0.4784314 rgBT /Ove	4.7	14
102	Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2016, 1, e000109.	4.5	2
103	The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 9-20.	4.4	87
104	Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. <i>Breast</i> , 2016, 27, 187-188.	2.2	1
105	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	4.6	442
106	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 738-746.	10.7	778
107	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , 2016, 139, 2859-2864.	5.1	94
108	Postoperative radiotherapy for non-small cell lung cancer. , 2016, 9, CD002142.		25

#	ARTICLE	IF	CITATIONS
109	Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics. <i>Advances in Therapy</i> , 2016, 33, 1305-1315.	2.9	6
110	Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 501-509.	2.5	49
111	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. <i>Tumori</i> , 2016, 102, 108-113.	1.1	4
112	Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural economic status, awareness of disease and the relation with the oncologist. <i>European Journal of Internal Medicine</i> , 2016, 33, e18-e19.	2.2	4
113	Reply to the letter to the editor "A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma" by Hines et al.. <i>Annals of Oncology</i> , 2016, 27, 1171.	1.2	0
114	A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. <i>Annals of Oncology</i> , 2016, 27, 274-280.	1.2	111
115	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. <i>Blood</i> , 2016, 128, 511-511.	1.4	13
116	Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy in unfit or older metastatic colorectal cancer patients: A systematic review and pooled-analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 705-705.	1.6	0
117	Efficacy and safety of bevacizumab in elderly or unfit patients with metastatic colorectal cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15029-e15029.	1.6	0
118	Abstract 3943: Baseline LDH serum level as predictive value of activity in patients treated with anti PD-1 and PDL-1 monoclonal antibodies. , 2016, , .		0
119	Hyperfractionated or accelerated radiotherapy for head and neck cancer. <i>The Cochrane Library</i> , 2015, 2015, .	2.8	52
120	Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 728-733.	2.7	3
121	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 479-482.	1.3	26
122	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. <i>Oncotarget</i> , 2015, 6, 35087-35094.	1.8	40
123	EGFR mutations and EGFR tyrosine kinase inhibitors. <i>Lancet Oncology</i> , The, 2015, 16, 746-748.	10.7	3
124	Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. <i>The Cochrane Library</i> , 2015, 2015, CD011430.	2.8	158
125	Predictive Value of Heidelberg Retina Tomograph Parameters for the Development of Glaucoma in the European Glaucoma Prevention Study. <i>American Journal of Ophthalmology</i> , 2015, 159, 265-276.e1.	3.3	8
126	Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. <i>Clinical and Translational Oncology</i> , 2015, 17, 530-538.	2.4	2



#	ARTICLE	IF	CITATIONS
127	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 213-227.	4.4	51
128	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015, 26, 300-306.	1.2	77
129	Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population. <i>International Journal of Cardiology</i> , 2015, 186, 170-177.	1.7	10
130	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. <i>Annals of Oncology</i> , 2015, 26, 2079-2084.	1.2	42
131	Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of <i>HER2</i> -Amplified Gastrointestinal Carcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 5519-5531.	7.0	84
132	Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. <i>Journal of Bone and Mineral Metabolism</i> , 2015, 33, 119-124.	2.7	31
133	Olfactory System of Highly Trained Dogs Detects Prostate Cancer in Urine Samples. <i>Journal of Urology</i> , 2015, 193, 1382-1387.	0.4	96
134	Trastuzumab and lapatinib in <i>HER2</i> -amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3508-3508.	1.6	27
135	Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8048-8048.	1.6	1
136	Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 390-396.	1.1	123
137	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014, 10, 1361-1372.	2.4	9
138	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii113-iii123.	1.2	212
139	Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study. <i>International Journal of Breast Cancer</i> , 2014, 2014, 1-7.	1.2	42
140	Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee. <i>Lung Cancer</i> , 2014, 85, 74-80.	2.0	12
141	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 713-721.	10.7	157
142	Afatinib for lung cancer: let there be light?. <i>Lancet Oncology</i> , The, 2014, 15, 133-134.	10.7	4
143	DRAGO (KIAA0247), a New DNA Damage-Responsive, p53-Inducible Gene That Cooperates With p53 as Oncosuppressor. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju053.	6.3	19
144	The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. <i>Cancer Treatment Reviews</i> , 2014, 40, 485-494.	7.7	21

#	ARTICLE	IF	CITATIONS
145	Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?. <i>Journal of Clinical Oncology</i> , 2014, 32, 859-863.	1.6	3
146	Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 363.e1-363.e10.	1.3	62
147	Clinical Outcome of HER2-positive Breast Cancer Patients after Failure on Adjuvant Trastuzumab: The Potential of the Time to Relapse. <i>Clinical Oncology</i> , 2014, 26, 174.	1.4	2
148	Efficacy of biological agents in metastatic triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 605-613.	7.7	43
149	HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11591-e11591.	1.6	0
150	The natural history of HER2-overexpressing (HER2+) metastatic breast cancer (MBC) treated with trastuzumab (T): Practical points to consider in developing treatment strategies.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11565-e11565.	1.6	0
151	Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis. <i>Tumori</i> , 2014, 100, 426-31.	1.1	0
152	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 981-988.	10.7	472
153	Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. <i>Annals of Oncology</i> , 2013, 24, 3028-3034.	1.2	66
154	Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2013, 49, 520-530.	2.8	141
155	Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the art and recommendations. <i>Cancer Treatment Reviews</i> , 2013, 39, 328-339.	7.7	51
156	The Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors. <i>Acta Ophthalmologica</i> , 2013, 91, e612-e619.	1.1	11
157	To Target or Not to Target, That Is the Question. <i>Journal of Clinical Oncology</i> , 2013, 31, 1254-1254.	1.6	3
158	DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. <i>Pharmacogenomics Journal</i> , 2013, 13, 159-172.	2.0	16
159	Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e59981.	2.5	28
160	Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly. <i>PLoS ONE</i> , 2012, 7, e36411.	2.5	167
161	Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 172-178.	1.6	223
162	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , 2012, 65, 218-223.	2.0	35

#	ARTICLE	IF	CITATIONS
163	Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the "SENDO experience". Annals of Oncology, 2012, 23, 1416-1421.	1.2	78
164	Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer—subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Annals of Oncology, 2012, 23, 2771-2772.	1.2	1
165	SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. Journal of Proteomics, 2012, 76, 91-101.	2.4	67
166	Evidence-based guidelines: Improving AGREement on consistence evaluation. Journal of Bone Oncology, 2012, 1, 30-34.	2.4	0
167	The effect of changes in intraocular pressure on the risk of primary open-angle glaucoma in patients with ocular hypertension: an application of latent class analysis. BMC Medical Research Methodology, 2012, 12, 151.	3.1	9
168	Comment on: "Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice" (Magnani P, Conforti A, Zanolin E, Marzotto M and Bellavite P.) Tj ETQq0 0 0 rgBT /Overlock 10.If 50 537 Td (Psych		
169	Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis. Digestive and Liver Disease, 2011, 43, 286-294.	0.9	39
170	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. Lung Cancer, 2011, 72, 378-383.	2.0	56
171	A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP) Tj ETQq1 1 0.734314 rgBT /Over		
172	Antibiotics versus surgery for appendicitis. Lancet, The, 2011, 378, 1067-1068.	18.7	2
173	Amyotrophic Lateral Sclerosis Multiprotein Biomarkers in Peripheral Blood Mononuclear Cells. PLoS ONE, 2011, 6, e25545.	2.5	123
174	Switch Maintenance versus Second-Line Treatment in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1298.	1.1	1
175	Dipyridamole stress echocardiography in diagnosis and prognosis of hemodialysis patients with asymptomatic coronary disease. Hemodialysis International, 2011, 15, 468-476.	0.9	2
176	Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Annals of Oncology, 2011, 22, 2424-2430.	1.2	57
177	A Joint Model for Prognostic Effect of Biomarker Variability on Outcomes: long-term intraocular pressure (IOP) fluctuation on the risk of developing primary open-angle glaucoma (POAG). JP Journal of Biostatistics, 2011, 5, 73-96.	0.0	4
178	Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta-analysis. Journal of Magnetic Resonance Imaging, 2010, 31, 19-31.	3.4	219
179	Looking for efficiency rather than efficacy in randomized controlled trials in oncology. Annals of Oncology, 2010, 21, 1391-1393.	1.2	2
180	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. Journal of Clinical Oncology, 2010, 28, 3219-3226.	1.6	1,352

#	ARTICLE	IF	CITATIONS
181	Malignant peritoneal mesothelioma: a multicenter study on 81 cases. <i>Annals of Oncology</i> , 2010, 21, 348-353.	1.2	101
182	Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2010, 70, 119-128.	2.0	58
183	Do we need biopsies of metastases for colorectal cancer patients?. <i>British Journal of Cancer</i> , 2009, 101, 374-375.	6.4	2
184	Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1500-1508.	3.6	191
185	High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment—Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria. <i>Radiology</i> , 2009, 251, 447-456.	7.3	198
186	Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer. <i>Investigational New Drugs</i> , 2009, 27, 179-183.	2.6	20
187	Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. <i>The Cochrane Library</i> , 2009, , CD000022.	2.8	121
188	A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. <i>Annals of Oncology</i> , 2009, 20, 660-665.	1.2	114
189	Autoimmune disorders in patients affected by celiac sprue and inflammatory bowel disease. <i>Annals of Medicine</i> , 2009, 41, 139-143.	3.8	30
190	CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. <i>Lancet Oncology</i> , The, 2009, 10, 877-884.	10.7	226
191	Exenatide for type 2 diabetes. <i>Lancet</i> , The, 2009, 373, 122.	13.7	0
192	Differential diagnosis and management of focal ground-glass opacities. <i>European Respiratory Journal</i> , 2009, 33, 821-827.	6.7	72
193	Effects of Transdermal Buprenorphine on Patients-reported Outcomes in Cancer Patients. <i>Clinical Journal of Pain</i> , 2009, 25, 671-682.	1.9	8
194	Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. <i>Anticancer Research</i> , 2009, 29, 2691-701.	1.1	27
195	Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials. <i>Trials</i> , 2008, 9, 46.	1.6	4
196	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , 2008, 99, 51-56.	6.4	107
197	Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1707-1716.	6.3	1,316
198	Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 3552-3559.	1.6	2,119

#	ARTICLE	IF	CITATIONS
199	Analysis of Gene Expression in Early-Stage Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7850-7860.	7.0	43
200	Impact of recent legislative bills regarding clinical research on Italian ethics committee activity. <i>Journal of Medical Ethics</i> , 2008, 34, 747-750.	1.8	11
201	Should <i>KRAS</i> Mutations Be Considered an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab?. <i>Journal of Clinical Oncology</i> , 2008, 26, 2600-2600.	1.6	5
202	A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. <i>British Journal of Cancer</i> , 2008, 98, 720-727.	6.4	8
203	Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 4906-4911.	1.6	530
204	Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. <i>Journal of the National Cancer Institute</i> , 2008, 100, 388-398.	6.3	123
205	Predicting response of molecular targeted therapies: a still possible challenge?. <i>Annals of Oncology</i> , 2008, 19, 829-830.	1.2	3
206	Paclitaxel plus Bevacizumab for Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 1637-1638.	27.0	14
207	Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. <i>Annals of Oncology</i> , 2007, 18, 1660-1665.	1.2	116
208	Bevacizumab for Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 1373-1375.	27.0	12
209	Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3831-3839.	7.0	221
210	Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epirubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 601-607.	6.3	96
211	Predictive Factors for Open-Angle Glaucoma among Patients with Ocular Hypertension in the European Glaucoma Prevention Study. <i>Ophthalmology</i> , 2007, 114, 3-9.	5.2	291
212	Central Corneal Thickness in the European Glaucoma Prevention Study. <i>Ophthalmology</i> , 2007, 114, 454-459.	5.2	56
213	Validated Prediction Model for the Development of Primary Open-Angle Glaucoma in Individuals with Ocular Hypertension. <i>Ophthalmology</i> , 2007, 114, 10-19.e2.	5.2	295
214	Intercurrent Factors Associated with the Development of Open-Angle Glaucoma in the European Glaucoma Prevention Study. <i>American Journal of Ophthalmology</i> , 2007, 144, 266-275.e1.	3.3	166
215	An Oxaliplatin + 5-Fluorouracil Bolus + Folinic Acid (BFOL) Regimen as First-Line Treatment in Metastatic Colorectal Cancer Patients. <i>Tumori</i> , 2007, 93, 557-561.	1.1	0
216	Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 7.	2.4	23

#	ARTICLE	IF	CITATIONS
217	Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. <i>British Journal of Cancer</i> , 2006, 95, 699-704.	6.4	268
218	Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study. <i>Investigational New Drugs</i> , 2006, 25, 57-62.	2.6	5
219	Methodology of clinical research: an overview. <i>Drug Development Research</i> , 2006, 67, 183-187.	2.9	0
220	Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. <i>International Journal of Cancer</i> , 2006, 118, 628-632.	5.1	57
221	Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study. <i>Oncology</i> , 2006, 71, 374-381.	1.9	14
222	Sampling variability of computer-aided fractal-corrected measures of liver fibrosis in needle biopsy specimens. <i>World Journal of Gastroenterology</i> , 2006, 12, 7660.	3.3	9
223	Differentiation of Small Adnexal Masses Based on Morphologic Characteristics of Transvaginal Sonographic Imaging. <i>Journal of Ultrasound in Medicine</i> , 2005, 24, 1467-1473.	1.7	20
224	Cost of Insurance Policies for Investigator-Initiated Cancer Clinical Trials in Italy. <i>Tumori</i> , 2005, 91, 373-379.	1.1	4
225	Effect of spinal degenerative changes on volumetric bone mineral density of the central skeleton as measured by quantitative computed tomography. <i>Acta Radiologica</i> , 2005, 46, 269-275.	1.1	61
226	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2005, 16, 1352-1358.	1.2	48
227	Randomized Trial of Neoadjuvant Chemotherapy Comparing Paclitaxel, Ifosfamide, and Cisplatin With Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 4137-4145.	1.6	189
228	Results of the European Glaucoma Prevention Study. <i>Ophthalmology</i> , 2005, 112, 366-375.	5.2	301
229	European Glaucoma Prevention Study. <i>Ophthalmology</i> , 2005, 112, 1642-1643.	5.2	27
230	European Glaucoma Prevention Study: Author reply. <i>Ophthalmology</i> , 2005, 112, 1643-1645.	5.2	131
231	The Impact of Definition of Primary Open-angle Glaucoma on the Cross-sectional Assessment of Diagnostic Validity of Heidelberg Retinal Tomography. <i>American Journal of Ophthalmology</i> , 2005, 139, 878-887.	3.3	16
232	Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6006-6012.	7.0	40
233	Patterns of Relapse and Modalities of Treatment of Breast Cancer: The â€œIRISâ€™ Project, a Multicenter Observational Study. <i>Oncology</i> , 2004, 66, 260-268.	1.9	8
234	Insurance for independent cancer trials. <i>Annals of Oncology</i> , 2004, 15, 1722-1723.	1.2	3

#	ARTICLE	IF	CITATIONS
235	Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004, 15, 28-32.	1.2	239
236	Randomized Trial of Intraportal and/or Systemic Adjuvant Chemotherapy in Patients With Colon Carcinoma. <i>Journal of the National Cancer Institute</i> , 2004, 96, 750-758.	6.3	24
237	Letter to the Editor. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 697-697.	2.5	0
238	Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the "Mario Negri" Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord) <i>Tj ETQ 0 0 rg BT /Overlo</i>	0.0	0
239	Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. , 2004, , CD000022.		169
240	Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. <i>Lung Cancer</i> , 2004, 43, 83-91.	2.0	58
241	Endometrial evaluation with transvaginal ultrasound during hormone therapy: a prospective multicenter study. <i>Fertility and Sterility</i> , 2004, 81, 1632-1637.	1.0	25
242	Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapyâ€”a multicenter randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 78-92.	0.8	112
243	Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1453-1461.	6.3	550
244	ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit. <i>Lancet, The</i> , 2003, 362, 1333.	13.7	2
245	ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit. <i>Lancet, The</i> , 2003, 362, 1334.	13.7	1
246	Reproducibility of evaluation of optic disc change for glaucoma with stereo optic disc photographs. <i>Ophthalmology</i> , 2003, 110, 340-344.	5.2	58
247	Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. <i>European Journal of Cancer</i> , 2003, 39, 1948-1956.	2.8	87
248	Using the Expected Survival to Explain Differences Between the Results of Randomized Trials: A Case in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1682-1687.	1.6	12
249	International Collaborative Ovarian Neoplasm Trial 1: A Randomized Trial of Adjuvant Chemotherapy in Women With Early-Stage Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 125-132.	6.3	256
250	Effectiveness of Adjuvant Fluorouracil in Elderly Colon Cancer Patients: The Internal and External Validity of Nonrandomized Research Design. <i>Journal of Clinical Oncology</i> , 2003, 21, 1892-1892.	1.6	2
251	Phase II Study of Taxol Combined With Ifosfamide and Carboplatin in the Treatment of Stage IIIbâ€”IV Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 84-88.	1.3	8
252	Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based Regimens. <i>Journal of Clinical Oncology</i> , 2002, 20, 1232-1237.	1.6	86

#	ARTICLE	IF	CITATIONS
253	Postoperative Hyperprolactinemia Could Predict Longer Disease-Free and Overall Survival in Node-Negative Breast Cancer Patients. <i>Oncology</i> , 2002, 63, 370-377.	1.9	7
254	Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. <i>Lancet, The</i> , 2002, 360, 505-515.	13.7	514
255	Simple, shared guidelines raise the quality of antihypertensive treatment in routine care. <i>American Heart Journal</i> , 2002, 144, 726-732.	2.7	11
256	The European glaucoma prevention study design and baseline description of the participants. <i>Ophthalmology</i> , 2002, 109, 1612-1621.	5.2	88
257	Simple, shared guidelines raise the quality of antihypertensive treatment in routine care. <i>American Heart Journal</i> , 2002, 144, 726-732.	2.7	12
258	HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. <i>Cancer</i> , 2002, 94, 2669-2674.	4.1	44
259	First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. <i>British Journal of Cancer</i> , 2002, 87, 815-824.	6.4	112
260	Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. <i>Critical Care Medicine</i> , 2001, 29, 1404-1407.	0.9	302
261	Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. <i>Annals of Oncology</i> , 2001, 12, 1179-1180.	1.2	38
262	Early stage ovarian cancer: the Italian contribution to clinical research. An update. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 12-19.	2.5	14
263	Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. <i>Annals of Oncology</i> , 2000, 11, 837-843.	1.2	339
264	Survey on the treatment of non-small-cell lung cancer in Italy. <i>Annals of Oncology</i> , 2000, 11, 807-813.	1.2	11
265	Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 1356-1356.	1.6	531
266	Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. <i>Journal of Neurology</i> , 1999, 246, 770-775.	3.6	105
267	ICON2 trial. <i>Lancet, The</i> , 1999, 353, 587.	13.7	4
268	The Long-term Prognostic Significance of Repeated Blood Pressure Measurements in the Elderly. <i>Archives of Internal Medicine</i> , 1999, 159, 1205.	3.8	49
269	Inconclusive messages from equivalence trials in thrombolysis. <i>Heart</i> , 1999, 81, 675-676.	2.9	9
270	First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. <i>British Journal of Cancer</i> , 1998, 78, 1471-1478.	6.4	32



#	ARTICLE	IF	CITATIONS
271	Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. <i>British Journal of Cancer</i> , 1998, 78, 1479-1487.	6.4	210
272	GIVIO-SITAC 01. , 1998, 82, 2135-2144.		59
273	The multi-centre assessment of quality of life: the Interdisciplinary Group for Cancer Care Evaluation (GIVIO) experience in Italy. , 1998, 17, 577-585.		13
274	Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. <i>Statistics in Medicine</i> , 1998, 17, 2815-2834.	1.6	4,325
275	Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. <i>Italian Journal of Neurological Sciences</i> , 1998, 19, 32-36.	0.1	16
276	ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. <i>Lancet, The</i> , 1998, 352, 1571-1576.	13.7	171
277	Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. <i>Lancet, The</i> , 1998, 352, 257-263.	13.7	816
278	Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyl-doxorubicin and its metabolites. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 235-240.	2.3	20
279	Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 1998, 316, 1275-1285.	2.3	377
280	Elevated cerebrospinal fluid levels of monocyte chemoattractant protein-1 correlate with HIV-1 encephalitis and local viral replication. <i>Aids</i> , 1998, 12, 1327-1332.	2.2	226
281	Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3439-3460.	1.6	535
282	Cerebrospinal fluid HIV-1 RNA levels. <i>Aids</i> , 1998, 12, 389-394.	2.2	116
283	The accuracy of staging: An important prognostic determinant in stage I ovarian carcinoma. <i>Annals of Oncology</i> , 1998, 9, 1097-1101.	1.2	85
284	How CA 125 Is Used in the Routine Follow-Up of Ovarian Cancer:A Survey of 29 Italian Hospitals. <i>Tumor Biology</i> , 1998, 19, 269-274.	1.8	3
285	Assessing the effectiveness of follow-up care for colorectal cancer: A great conceptual and methodological challenge for clinical oncology. <i>Annals of Oncology</i> , 1997, 8, 1059-1062.	1.2	6
286	Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. <i>British Journal of Cancer</i> , 1997, 75, 878-883.	6.4	28
287	Expression of Genes of Potential Importance in the Response to Chemotherapy and DNA Repair in Patients with Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 65, 130-137.	1.4	53
288	Conservative surgery for Stage I ovarian carcinoma in women of childbearing age. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1997, 104, 1030-1035.	2.3	186

#	ARTICLE	IF	CITATIONS
289	Beware of Surrogate Outcome Measures. <i>International Journal of Technology Assessment in Health Care</i> , 1996, 12, 238-246.	0.5	94
290	Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 325-332.	0.1	11
291	Sonographic endometrial thickness: a useful test to predict atrophy in patients with postmenopausal bleeding. An Italian multicenter study. <i>Ultrasound in Obstetrics and Gynecology</i> , 1996, 7, 315-321.	1.7	153
292	Clinical Profile of Ioversol. <i>Investigative Radiology</i> , 1996, 31, 479-491.	6.2	4
293	Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study. <i>BMJ: British Medical Journal</i> , 1996, 313, 1110-1113.	2.3	65
294	Epidemic HIV-related Kaposi's sarcoma: A retrospective analysis and validation of TIS staging. <i>Annals of Oncology</i> , 1995, 6, 383-387.	1.2	10
295	A proposal for a new approach to intergroup cancer trials. <i>European Journal of Cancer</i> , 1995, 31, 1921-1923.	2.8	2
296	Factors Predicting Response to Chemotherapy and Survival in Patients with Metastatic or Recurrent Squamous Cell Cervical Carcinoma: A Multivariate Analysis. <i>Gynecologic Oncology</i> , 1995, 58, 58-63.	1.4	22
297	Double-Blind Trial of Dexamethasone versus Methylprednisolone in Multiple Sclerosis Acute Relapses. <i>European Neurology</i> , 1994, 34, 199-203.	1.4	80
298	Controversial Issues in the Management of Early Epithelial Ovarian Cancer: Conservative Surgery and Role of Adjuvant Therapy. <i>Gynecologic Oncology</i> , 1994, 55, S47-S51.	1.4	101
299	Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly. <i>European Heart Journal</i> , 1994, 15, 206-212.	2.2	21
300	A limited sampling model for the pharmacokinetics of etoposide given orally. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 482-486.	2.3	29
301	Clinical Considerations on Side-Locked Unilaterality in Long-Lasting Primary Headaches. <i>Headache</i> , 1993, 33, 381-384.	3.9	55
302	Cell kinetics in management of ovarian cancer. <i>European Journal of Cancer</i> , 1993, 29, 169.	2.8	0
303	Randomized Clinical Trials on Medical Treatment of Glaucoma. <i>JAMA Ophthalmology</i> , 1993, 111, 96.	2.4	90
304	Dose intensity analysis in advanced ovarian cancer patients. <i>British Journal of Cancer</i> , 1993, 67, 190-197.	6.4	16
305	Inappropriate Halsted mastectomy and patient volume in Italian hospitals.. <i>American Journal of Public Health</i> , 1993, 83, 1762-1764.	2.7	15
306	Relationship Between Response and Survival in Patients With Advanced Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 1992, 84, 899-899.	6.3	6

#	ARTICLE	IF	CITATIONS
307	Statistical Model to Determine the Relationship of Response and Survival in Patients With Advanced Ovarian Cancer Treated With Chemotherapy. <i>Journal of the National Cancer Institute</i> , 1992, 84, 407-413.	6.3	55
308	Effect of selective decontamination of the digestive tract (SSD) upon mortality. <i>Contemporary Clinical Trials</i> , 1992, 13, 391.	1.9	0
309	Randomized clinical trials on medical treatment of glaucoma: Are they appropriate to guide clinical practice?. <i>Contemporary Clinical Trials</i> , 1992, 13, 421.	1.9	2
310	Methodological issues in screening for relapse in early breast cancer. <i>Contemporary Clinical Trials</i> , 1992, 13, 426.	1.9	0
311	Selective decontamination of digestive tract. <i>Lancet</i> , The, 1991, 338, 1389-1390.	13.7	1
312	Efficacy of intraportal infusion for colon cancer: a fair assessment?. <i>Journal of Clinical Oncology</i> , 1991, 9, 888-889.	1.6	0
313	The role of attitudes, beliefs, and personal characteristics of Italian physicians in the surgical treatment of early breast cancer.. <i>American Journal of Public Health</i> , 1991, 81, 38-42.	2.7	68
314	A SURVEY OF THE NECESSITY OF THE HOSPITALIZATION DAY IN AN ITALIAN TEACHING HOSPITAL. <i>International Journal for Quality in Health Care</i> , 1991, 3, 1-9.	1.8	19
315	Valproate, Carnitine Metabolism, and Biochemical Indicators of Liver Function. <i>Epilepsia</i> , 1990, 31, 346-352.	5.1	62
316	Prognostic factors in advanced epithelial ovarian cancer. <i>British Journal of Cancer</i> , 1990, 62, 444-450.	6.4	73
317	Â-P-35 The impact of management guidelines on quality of breast, colorectal and ovarian cancer in community hospitals. <i>Contemporary Clinical Trials</i> , 1990, 11, 291.	1.9	0
318	Trends in Patterns of Care for Breast Cancer in Italy (1979-1987). <i>Tumori</i> , 1990, 76, 184-189.	1.1	7
319	The impact of cancer treatment guidelines on actual practice in Italian general hospitals: The case of ovarian cancer. <i>Annals of Oncology</i> , 1990, 1, 112-118.	1.2	17
320	Quality, Evolution, and Clinical Implications of Randomized, Controlled Trials on the Treatment of Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 1989, 262, 2101.	7.4	50
321	Flow cytometric analysis of DNA content in human ovarian cancers. <i>British Journal of Cancer</i> , 1989, 60, 45-50.	6.4	62
322	Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin. <i>Journal of the National Cancer Institute</i> , 1989, 81, 1464-1471.	6.3	135
323	What doctors tell patients with breast cancer about diagnosis and treatment: Findings from a study in general hospitals. GIVIO (Interdisciplinary Group for Cancer Care Evaluation) Italy. <i>British Journal of Cancer</i> , 1986, 54, 319-326.	6.4	52